Organization | KangWon National University

KangWon National University Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Chuncheon Korea, Republic of (1947)

Organization Overview

First Clinical Trial

2010

NCT01491256

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

KangWon National University Hospital | Kangwon National University Hospital of Korea

Active Ingredients

Drugs in Phase 4 Trials (6)

magnesium sulfate (Tis-U-Sol) (1 trial)

polyethylene glycol (1 trial)

potassium chloride (klor-con) (1 trial)

potassium sulfate (1 trial)

sodium sulfate (1 trial)

vitamin c (1 trial)

Drugs in Phase 3 Trials (4)

5,7-dihydroxy-3',4',6-trimethoxyflavone (1 trial)

melatonin (1 trial)

moxifloxacin (avelox) (1 trial)

zabofloxacin (1 trial)

Drugs in Other Trials (2)

atorvastatin (lipitor) (1 trial)

nicorandil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Gastritis (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 12